Tract Bio Appoints Chris Galloway, M.D., as Chief Medical and Development Officer and Expands Board of Directors

-- Chris Galloway, M.D., brings over two decades of medical practice, clinical development and leadership experience across therapeutic areas, including oncology and immunology, and will oversee a drug development pipeline of novel therapies leveraging Tract Bio's proprietary stemECHO™ technology --

-- Leadership team update builds on recent appointments of Mark J. Adler, M.D., and Kristiina Vuori, M.D., Ph.D., to Board of Directors --

BOSTON, July 15, 2025 /PRNewswire/ -- Tract Bio, a biotechnology company discovering and developing novel therapies for cancer and inflammatory disease, today announced the appointment of Chris Galloway, M.D., as Chief Medical and Development Officer. In addition, Mark J. Adler, M.D., and Kristiina Vuori, M.D., Ph.D., recently joined the Company's Board of Directors.

"We are delighted to welcome Chris to Tract as we achieve tremendous progress across our unique stemECHO platform and emerging pipeline," said Richard Russell, Chief Executive Officer of Tract Bio. "Chris' clinical development experience, regulatory expertise and strategic insights will be critical to our efforts to advance novel therapies that target pathogenic stem cells for the treatment of highly prevalent chronic inflammatory diseases and cancer."

He will oversee the Company's plan to submit an IND for its lead solid tumor program, TP-101, in the next 18 months.

"The preclinical data for TP-101 provides compelling validation of Tract's approach to addressing diseases that are resistant to first-line therapies and currently have no effective treatment options. I look forward to contributing to Tract's mission to transform care for areas of high unmet need," said Galloway.

Dr. Galloway brings extensive experience in leadership, clinical development, medical affairs and business development. Before joining Tract, he was Senior Vice President of Clinical Development and Medical Affairs at Elevar Therapeutics. Prior to Elevar, he was Chief Medical Officer at Diffusion Pharmaceuticals and Senior Medical Director, Critical Care at La Jolla Pharmaceutical Company (acquired by Innoviva Specialty Therapeutics). Earlier in his career, he was Global Medical Director at Rakuten Medical, Director of Medical Affairs at Merck and Medical Director and Principal Investigator at DaVita Clinical Research. He has successfully overseen multiple IND, NDA and BLA submissions, engaged with global regulatory bodies and managed clinical development and medical affairs teams across a broad range of therapeutic areas, including oncology, immunology, rare disease and critical care. Dr. Galloway received his M.D. from the University of Texas Medical Branch at Galveston, completed his residency in emergency medicine at Carolinas Medical Center in Charlotte, N.C. and holds a B.A. in biology from the University of Texas at Austin.

Tract also welcomes two recent Board appointments, Mark J. Adler and Kristiina Vuori, both of whom are distinguished leaders in oncology. Richard Russell says Mark and Kristiina will be instrumental in positioning Tract for long-term success.

Dr. Adler was previously Founder and Chief Executive Officer at the San Diego Cancer Center (acquired by the University of California), which became the region's leading independent oncology institution. As founding Chief Executive Officer, he served as on-site principal investigator on pivotal trials, including those which ushered the first genome-targeted therapies. Prior, he was a founding Director of WebMD (acquired by Internet Brands), where he helped lead its acquisition of Medscape and its growth into the world's foremost platform for physician education and CME. He currently serves on the Board of Directors of Forian and XZOM. Previously, he served on the Board of Directors of CareInsite (acquired by Healtheon/WebMD) and Medical Manager (acquired by Healtheon/WebMD). Dr. Adler received his M.D. from the University of Pennsylvania and completed his residency at the University of Pennsylvania and fellowship in hematology/oncology at UC San Diego. At the Wistar Institute, he was awarded the National Institutes of Health (NIH) Physician-Scientist Award for his work on cancer and cellular senescence. He holds a B.A. in philosophy from Yale University.

Dr. Vuori is currently the President and Chief Executive Officer at Sanford Laboratories for Innovative Medicines, a not-for-profit biomedical research institution. Additionally, she serves as Professor and Pauline & Stanley Foster Distinguished Chair at Sanford Burnham Prebys Medical Discovery Institute (SBP), where she directs a cancer research laboratory. She held several leadership roles at SBP, including serving as President of the Institute and Director of SBP's National Cancer Institute-designated Cancer Center. She has published more than 100 research articles and received numerous research awards from the NIH, National Cancer Institute, Department of Defense, Stand Up to Cancer Dream Team and California Cancer Research Programs. She is a PEW Biomedical Scholar and an elected member of the National Academy of Inventors. She currently serves on several scientific advisory and review boards and serves or has served on the governing boards of American Association for Cancer Research, California Institute for Regenerative Medicine, California Breast Cancer Research Program, Bionano Genomics, Sio Gene Therapies, Forian, Inhibrx and WebMD (acquired by Internet Brands). Dr. Vuori received her M.D. and Ph.D. from the University of Oulu, Finland and completed a research fellowship at SBP (previously La Jolla Cancer Research Foundation) before joining the faculty of the Institute's National Cancer Institute-designated Cancer Center.

About Tract Bio
Tract Bio is a biotechnology company discovering and developing novel therapies to transform treatment of cancer and inflammatory disease. The Company's breakthrough stem cell discovery platform, stemECHO™, allows for reliable, high-volume generation of pure stem cell libraries in their ground-state while preserving the functional, genetic and epigenetic integrity of the original stem cell. The stemECHO™ platform has identified disease-associated stem cells in cancer and inflammatory diseases, including potential treatments for esophageal adenocarcinoma, lung, pancreatic, ovarian and gastric cancer, as well as COPD, Idiopathic Pulmonary Fibrosis, Cystic Fibrosis and Crohn's Disease. Tract is advancing TP-101, a novel drug combination identified using stemECHO™ that targets a common mechanism among disease-associated stem cells in cancer. The Company is also developing novel therapies for inflammatory diseases.

Contacts:
Investors/Media
Argot Partners
[email protected]

SOURCE Tract Bio